Review article: HCV genotype 3 – the new treatment challenge (Q26864571)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24612116%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

review article

1 reference

title

Review article: HCV genotype 3 – the new treatment challenge (English)

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24612116%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24612116%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Manuel Romero-Gomez

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24612116%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

author name string

K R Reddy

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24612116%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

language of work or name

1 reference

1 April 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24612116%20AND%20SRC:MED&resulttype=core&format=json

Alimentary Pharmacology & Therapeutics

10 March 2020

published in

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24612116%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

volume

39

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24612116%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

page(s)

686-698

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24612116%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

issue

7

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24612116%20AND%20SRC:MED&resulttype=core&format=json

The oncogenic role of hepatitis C virus

10 March 2020

cites work

1 reference

The role of viral and host genetics in natural history and treatment of chronic HCV infection.

21 January 2018

1 reference

Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

21 January 2018

1 reference

Emerging treatments for hepatitis C.

21 January 2018

1 reference

Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype 3.

21 January 2018

1 reference

Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes

21 January 2018

1 reference

The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide

21 January 2018

1 reference

Hepatitis C genotype 4: What we know and what we don't yet know.

21 January 2018

1 reference

Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6.

21 January 2018

1 reference

Global epidemiology of hepatitis C virus infection

21 January 2018

1 reference

Frequency distribution of hepatitis C virus genotypes in different geographical regions of Pakistan and their possible routes of transmission

21 January 2018

1 reference

Changing HCV genotypes distribution in Poland--relation to source and time of infection.

21 January 2018

1 reference

Relationship between hepatitis C virus genotypes and sources of infection in patients with chronic hepatitis C.

21 January 2018

1 reference

Hepatitis C virus genotypes distribution and transmission risk factors in Luxembourg from 1991 to 2006

21 January 2018

1 reference

Epidemiological changes in hepatitis C virus genotypes in France: evidence in intravenous drug users

21 January 2018

1 reference

Molecular epidemiology of hepatitis C virus subtype 3a in injecting drug users

21 January 2018

1 reference

Comparison of Hepatitis C Virus Genotyping by 5' Noncoding Region- and Core-Based Reverse Transcriptase PCR Assay with Sequencing and Use of the Assay for Determining Subtype Distribution in India

21 January 2018

1 reference

Molecular epidemiology and genetic history of hepatitis C virus subtype 3a infection in Thailand

21 January 2018

1 reference

Steatosis and insulin resistance in response to treatment of chronic hepatitis C.

21 January 2018

1 reference

Associations of chronic hepatitis C with metabolic and cardiac outcomes

21 January 2018

1 reference

Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity

21 January 2018

1 reference

Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C.

21 January 2018

1 reference

Specific Polymorphisms in Hepatitis C Virus Genotype 3 Core Protein Associated with Intracellular Lipid Accumulation

21 January 2018

1 reference

Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3.

21 January 2018

1 reference

HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis

21 January 2018

1 reference

Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected].

21 January 2018

1 reference

Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis

21 January 2018

1 reference

Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C.

21 January 2018

1 reference

Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.

21 January 2018

1 reference

Meta-analysis: insulin resistance and sustained virological response in hepatitis C.

21 January 2018

1 reference

Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3.

21 January 2018

1 reference

Insulin resistance predicts sustained virological response to treatment of chronic hepatitis C independently of the IL28b rs12979860 polymorphism

21 January 2018

1 reference

Hepatitis C Virus Down-Regulates Insulin Receptor Substrates 1 and 2 through Up-Regulation of Suppressor of Cytokine Signaling 3

21 January 2018

1 reference

Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes

21 January 2018

1 reference

Hepatitis C virus core protein genotype 3a increases SOCS-7 expression through PPAR-{gamma} in Huh-7 cells

21 January 2018

1 reference

Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance

21 January 2018

1 reference

Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor

21 January 2018

1 reference

Hepatitis C virus NS5A colocalizes with the core protein on lipid droplets and interacts with apolipoproteins

21 January 2018

1 reference

Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner

21 January 2018

1 reference

Up-regulation of fatty acid synthase promoter by hepatitis C virus core protein: genotype-3a core has a stronger effect than genotype-1b core

21 January 2018

1 reference

Diagnosis, management, and treatment of hepatitis C: an update

21 January 2018

1 reference

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.

21 January 2018

1 reference

Individualized treatment with combination of Peg-interferon alpha 2b and ribavirin in patients infected with HCV genotype 3.

21 January 2018

1 reference

'Easy to treat' genotypes were not created equal: can rapid virological response (RVR) level the playing field?

21 January 2018

1 reference

Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection

21 January 2018

1 reference

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis

21 January 2018

1 reference

Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C.

21 January 2018

1 reference

Role of hepatitis C virus genotype 3 in liver fibrosis progression--a systematic review and meta-analysis

21 January 2018

1 reference

Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3.

21 January 2018

1 reference

Is genotype 3 of the hepatitis C virus the new villain?

21 January 2018

1 reference

Steatosis is the predictor of relapse in HCV genotype 3- but not 2-infected patients treated with 12 weeks of pegylated interferon-α-2a plus ribavirin and RVR.

21 January 2018

1 reference

Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin.

21 January 2018

1 reference

Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study

21 January 2018

1 reference

Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response

21 January 2018

1 reference

Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin

21 January 2018

1 reference

Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.

21 January 2018

1 reference

Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin.

21 January 2018

1 reference

EASL Clinical Practice Guidelines: management of hepatitis C virus infection

21 January 2018

1 reference

Telaprevir for previously untreated chronic hepatitis C virus infection

21 January 2018

1 reference

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections

21 January 2018

1 reference

Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3.

21 January 2018

1 reference

Hepatitis C virus: standard-of-care treatment

21 January 2018

1 reference

New horizons in hepatitis C antiviral therapy with direct-acting antivirals.

21 January 2018

1 reference

Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.

21 January 2018

1 reference

Treatment of patients with genotype 3 chronic hepatitis C--current and future therapies

21 January 2018

1 reference

Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study

21 January 2018

1 reference

NS5A--from obscurity to new target for HCV therapy

21 January 2018

1 reference

NS5A inhibitor, daclatasvir, for the treatment of chronic hepatitis C virus infection.

21 January 2018

1 reference

Sofosbuvir, a nucleotide polymerase inhibitor, for the treatment of chronic hepatitis C virus infection

21 January 2018

1 reference

Sofosbuvir (GS-7977), a pan-genotype, direct-acting antiviral for hepatitis C virus infection

21 January 2018

1 reference

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial

21 January 2018

1 reference

Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.

21 January 2018

1 reference

Sofosbuvir for previously untreated chronic hepatitis C infection

21 January 2018

1 reference

The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus.

21 January 2018

1 reference

The cyclophilin inhibitor Debio 025 combined with PEG IFNalpha2a significantly reduces viral load in treatment-naïve hepatitis C patients.

21 January 2018

1 reference

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options

21 January 2018

1 reference

HCV direct-acting antiviral agents: the best interferon-free combinations

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/APT.12646

2 references

Consolidated OpenCitations Corpus – April 2017

1370483

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24612116%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

1370483

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

2 references

1370483

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24612116%20AND%20SRC:MED&resulttype=core&format=json